Table 3.

Clinical TB score in vitD₃+PBA versus placebo

			Crude			Adjusteda
Endpoint	Week	n	Difference	95% CI	P Value	Difference	95% CI	P Value
All patients (mITT)
Primary TB score	4	348	−0.07	(−0.49 to 0.35)	0.741	−0.16	(−0.54 to 0.23)	0.425
	8	348	−0.42	(−0.90 to 0.06)	0.089	−0.52	(−0.93 to −0.10)	0.015
	16	348	−0.17	(−0.65 to 0.31)	0.483	−0.32	(−0.65 to 0.00)	0.051
Modified TB score	4	348	−0.13	(−0.80 to 0.54)	0.700	−0.24	(−0.77 to 0.29)	0.375
	8	348	−0.48	(−1.15 to 0.20)	0.165	−0.58	(−1.02 to −0.14)	0.010
	16	348	−0.19	(−0.88 to 0.49)	0.580	−0.34	(−0.64 to −0.03)	0.030
Patients (per-protocol)
Primary TB score	4	320	−0.10	(−0.54 to 0.33)	0.635	−0.17	(−0.55 to 0.25)	0.454
	8	309	−0.42	(−0.90 to 0.06)	0.087	−0.47	(−0.86 to −0.07)	0.022
	16	302	−0.22	(−0.71 to 0.28)	0.386	−0.30	(−0.61 to 0.01)	0.055
Modified TB score	4	320	−0.21	(−0.86 to 0.45)	0.533	−0.28	(−0.82 to 0.26)	0.315
	8	309	−0.53	(−1.23 to 0.17)	0.134	−0.62	(−1.11 to −0.11)	0.016
	16	302	−0.27	(−1.02 to 0.47)	0.474	−0.40	(−0.81 to 0.02)	0.060
Patients with 25(OH)D3 ≤50 nmol/l + TB score >5 (per-protocol)
Primary TB score	4	125	−0.38	(−1.10 to 0.34)	0.296	−0.46	(−1.18 to 0.26)	0.209
	8	120	−1.12	(−1.90 to −0.34)	0.005	−1.11	(−1.89 to −0.34)	0.005
	16	118	−0.62	(−1.29 to 0.05)	0.070	−0.61	(−1.21 to 0.00)	0.051
Modified TB score	4	125	−0.84	(−1.74 to 0.06)	0.066	−0.89	(−1.79 to 0.01)	0.053
	8	120	−1.43	(−2.39 to −0.47)	0.004	−1.37	(−2.28 to −0.47)	0.003
	16	118	−0.91	(−1.83 to 0.01)	0.052	−0.83	(−1.61 to −0.06)	0.036

CI, confidence interval; mITT, modified intention-to-treat; 25(OH)D₃, 25-hydroxyvitamin D

^aData are adjusted for gender, age, and TB score and sputum-smear positivity at baseline.